The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
Status:
Withdrawn
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the effect of Velaglucerase Alfa on skeletal bone
development of children with Type 1 or Type 3 Gaucher Disease. In addition, the natural
history and neurological status of children with Type 3 Gaucher Disease will be studied.